An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
Cabozantinib
Efficacy
Non-clear renal cell carcinoma
Renal carcinoma
Toxicity
Tyrosine kinase receptor inhibitor
Vascular endothelial growth factor receptor
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
20
01
2020
revised:
27
02
2020
accepted:
28
02
2020
pubmed:
17
3
2020
medline:
10
5
2020
entrez:
16
3
2020
Statut:
ppublish
Résumé
Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.
Identifiants
pubmed: 32172222
pii: S1040-8428(20)30059-7
doi: 10.1016/j.critrevonc.2020.102921
pii:
doi:
Substances chimiques
Anilides
0
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Pyridines
0
cabozantinib
1C39JW444G
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102921Informations de copyright
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Authors declare no conflict of interest.